Is Epigenomics AG halal to invest in?

According to Musaffa's Shariah screening methodology, Epigenomics AG (ECX.F) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Epigenomics AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Epigenomics AG using these criteria to determine its compliance status.

Can Muslims buy shares of Epigenomics AG?

Muslim investors may consider investing in Epigenomics AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Epigenomics AG classified as NOT HALAL?

Musaffa determines the Shariah status of Epigenomics AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Epigenomics AG updated?

The Shariah compliance status of Epigenomics AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Epigenomics AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Epigenomics AG?

You can check the latest Shariah compliance status of Epigenomics AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Epigenomics AG ECX.F

€0.93

Last Updated: May 15, 12:00 AM·XFRA

ECX.F Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: January 20, 2026

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for Epigenomics AG (ECX.F)

Based on 10 analysts giving stock ratings to Epigenomics AG in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Epigenomics AG. Stock Analysis ECX.F

Germany Health Care Nano Cap Report: Q2, 2025

Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 3 full-time employees. The company went IPO on 2004-07-19. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.

Key Statistics of Epigenomics AG (ECX.F)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.93€0.94

Today's Open

€0.93

Volume

96.00

P/E Ratio (TTM)

52 Week Range

€0.51€1.59

Market Cap

810.00K

Avg. Volume

515.13

Dividend Yield

Financial Metrics & Statements of Epigenomics AG (ECX.F)

FAQ's for Epigenomics AG (ECX.F)

According to Musaffa’s Shariah screening methodology, Epigenomics AG (ECX.F) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.